TPST Tempest Therapeutics
- 3.420
- +0.180+5.56%
Tempest Therapeutics News
Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
PDF Version BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno
Tempest Announces Publication of Positive Data From Phase 1 Trial of TPST-1120 in Patients With Advanced Solid Tumors in Journal of Cancer Research Communications
PDF Version TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive r
Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles
Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)
Tempest Therapeutics (TPST) Receives a Buy From Scotiabank
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest FY23 EPS $(1.91) Vs $(3.09) YoY; Ended The Year With $39.2M In Cash And Cash Equivalents
Financial ResultsYear End 2023Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022. The increase was primarily due to proceeds from t
Tempest Therapeutics GAAP EPS of -$1.91 Beats by $0.03
Press Release: Tempest Reports Year End 2023 Financial Results and Provides Business Update
Tempest Reports Year End 2023 Financial Results and Provides Business Update -- Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across
Tempest Reports Year End 2023 Financial Results and Provides Business Update
Tempest Reports Year End 2023 Financial Results And Provides Business Update
PDF Version Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomark
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP ("GPM") announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors' and officers' possible
Express News | Scotiabank Initiates Coverage On Tempest Therapeutics With Sector Outperform Rating, Announces Price Target of $13
Buy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospects
Express News | HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therape
Express News | Tempest Announces Upcoming Presentation Of Preclinical Data For TPST-1120 In Renal Cell Carcinoma At AACR Annual Meeting
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
PDF Version BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune
Analysis
Price Target
No Data
